AstraZeneca: UBS is no longer a seller

(CercleFinance.com) - UBS has raised its recommendation on AstraZeneca from 'sell' to 'neutral', with the target price maintained at 11300 pence, a target which implies a potential upside of 13% for the Anglo-Swedish pharmaceutical company's shares.


Although the risks associated with China remain, we consider government approvals to be favorable in the medium term", says the broker, adding that a "PharmaValues EV/NPV ratio of 1.03 times adds support".

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.